Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
Status:
Completed
Trial end date:
2019-09-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton
pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information
about safety and tolerability will be collected. The study will last up to about 9 weeks,
inclusive of screening period.